Boutique webinar:
Multi-Omic Breakthroughs: Immune Monitoring for Precision Disease Detection
Introducing new approaches to immune monitoring
Helen McGuire, PhD, talks about how her team introduced a cutting-edge approach to immune monitoring that simplifies sample collection in multi-site clinical trials, particularly benefiting remote and underrepresented populations.
- Lung cancer immunotherapy response: A novel immune signature of lung cancer nonresponsiveness, developed using a 50-plus-marker CyTOF™ panel, can predict failure to respond to checkpoint therapies, offering a powerful tool for treatment decisions
- Plasma proteome analysis for disease detection: The SomaScan™ platform, which assesses over 11,000 proteins, is used to track disease progression and immune response in real time, opening up new possibilities for biomarker discovery
- Multi-omic data integration for enhanced predictability: Combining cellular and plasma-based immune data through advanced multi-omic integration can improve clinical outcome prediction
Watch to learn how you can apply these techniques to your own clinical trials and gain insights on how to improve disease detection, treatment effectiveness and overall trial outcomes.
Helen McGuire, PhD
Helen McGuire is a Senior Lecturer at the University of Sydney. Her interests are in emphasizing the use of technology to understand the role of the immune system in clinical applications of human disease. Following studies at UNSW and the Garvan Institute of Medical Research in Sydney, on an NHMRC ECR fellowship she undertook her postdoctoral training at Stanford University, and has subsequently pioneered the introduction of mass cytometry into the wider Australian research landscape.
Boutique webinar:
Multi-Omic Breakthroughs: Immune Monitoring for Precision Disease Detection
A presentation by Helen McGuire, PhD
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.